Charles River Laboratories International, Inc. — FY2012 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended December 29, 2012 (and includes unaudited fourth-quarter results). Charles River provides research models and related services (RMS) and outsourced preclinical services (PCS) to pharmaceutical, biotechnology, academic, and government customers. RMS generated 61.5% of 2012 sales; PCS generated 38.5%.
Key financial results
| Metric | FY2012 | FY2011 |
|---|---|---|
| Net sales | $1,129.5 million | $1,142.6 million |
| Gross margin | 35.0% | 35.2% |
| Operating income | $165.8 million; 14.7% margin | $174.3 million; 15.3% margin |
| Income from continuing operations, net of tax | $102.1 million | $115.5 million |
| Net income attributable to common shareholders | $97.3 million | $109.6 million |
| Diluted EPS | $2.01 | $2.14 |
| Cash from operating activities | $208.0 million | $206.8 million |
| Capital expenditures | $47.5 million | $49.1 million |
| Cash and cash equivalents, year-end | $109.7 million | $68.9 million |
| Total debt and capital lease obligations, year-end | $666.5 million | $717.9 million |
| Working capital, year-end | $143.0 million | $209.0 million |
2012 sales declined 1.1%, primarily reflecting a 2.0% unfavorable foreign-currency effect and the prior year’s extra fiscal week. Product sales were $467.9 million and service sales were $661.6 million. Segment sales fell 1.5% at RMS and 0.6% at PCS. RMS operating margin was essentially flat at 29.1%; PCS operating margin improved to 8.0% from 5.7%, mainly because 2011 included asset impairments and 2012 benefited from cost savings and lower amortization.
Fourth-quarter 2012 sales were $280.1 million, operating income was $35.1 million, and income from continuing operations was $22.7 million. Net income attributable to common shareholders was $18.4 million, including a $4.2 million after-tax discontinued-operations loss.
Material changes and liquidity
- Operating income declined $8.5 million and common-shareholder net income declined $12.3 million year over year. Management attributed the earnings decline in part to prior-year benefits, including a $7.7 million life-insurance gain and a tax valuation-allowance release; lower sales and fixed-cost absorption also weighed on results.
- Operating cash flow was nearly flat year over year. Cash increased by $40.8 million during 2012, while financing activities used $111.1 million, including $64.2 million for treasury stock purchases. The company repurchased 1.7 million shares for $61.4 million during the year.
- Year-end cash was predominantly held outside the U.S.: $99.0 million of $109.7 million. The company stated that certain foreign earnings are indefinitely reinvested and may incur material tax if repatriated.
- The $350 million 2.25% convertible notes mature in June 2013. The company intended to settle principal in cash and expected to use existing credit capacity, cash and marketable securities, or other financing. No conversion triggers had been met at year-end. The company reported compliance with its credit-facility financial covenants.
- Current debt maturities rose to $139.4 million from $14.8 million, while working capital fell to $143.0 million. The revolving credit facility had $32.0 million drawn against its $350 million commitment at year-end.
Outlook, commentary, and notable items
- Management described client demand as stabilizing but uncertain. It cited constrained R&D budgets, pipeline rationalization, pricing pressure, industry excess capacity, reduced biotechnology funding, and customer focus on later-stage programs as continuing headwinds. It saw potential longer-term opportunity in increased outsourcing, particularly non-GLP discovery and pharmacology services.
- No specific sales or earnings guidance was provided in the supplied filing text. Management expected 2013 capital expenditures of approximately $50 million and said existing capacity could support growth without significant expansion.
- Strategic investments included the August 2012 acquisition of Accugenix for $18.4 million in cash (net purchase price $16.9 million), and the January 2013 completion of the purchase of 75% of Vital River in China for approximately $26.8 million, subject to adjustments. The company also opened a diagnostic testing facility and expanded a Finland discovery-services facility.
- The company recorded a $3.5 million impairment tied to consolidation of certain RMS operations in Europe. It also recorded a $7.2 million contingent loss related to its guarantee of a lease for the discontinued Phase I clinical business; the related year-end liability was $9.7 million.
- Management and the auditor reported a material weakness in internal control over financial reporting as of year-end, involving segregation of duties, restricted system access, vendor/customer master-data changes, transaction-level controls, and financial-close controls. The auditor gave an unqualified opinion on the financial statements but an adverse opinion on internal control effectiveness. Remediation steps were initiated in the first quarter of 2013.
- Other key risks include client contract cancellations or reductions, dependence on pharmaceutical and government research spending, animal-population contamination, regulatory compliance, foreign-exchange exposure, competition and pricing, acquisitions and integration, and tax disputes. The filing reports no material legal proceedings apart from ordinary-course matters.
Important facts for investors to verify
- How the company plans to refinance or repay the $350 million convertible notes due June 2013, and the resulting effect on interest expense and liquidity.
- Progress and independent validation of remediation for the material weakness and ineffective disclosure controls.
- Whether sales and margins recover, especially in PCS, and whether cost savings offset pricing pressure and weak demand.
- Cash availability and tax implications given the concentration of cash and indefinitely reinvested earnings outside the U.S.
- Integration, performance, and purchase economics of Accugenix and Vital River, including the obligations and options concerning Vital River’s remaining 25% interest.
- The discontinued-business lease guarantee exposure and the potential for further payments if the lessee defaults.